Telix Pharmaceuticals (TLX) Accounts Payables (2023 - 2026)

Telix Pharmaceuticals (TLX) has reported Accounts Payables for 3 consecutive years, with $150.3 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Accounts Payables rose 234.66% year-over-year to $150.3 million; the TTM figure through Dec 2025 stood at $150.3 million (up 234.66% YoY), while the FY2025 annual figure was $150.3 million, up 73.23% from the prior year.
• Accounts Payables climbed to $150.3 million in Q4 2025 per TLX's latest filing, from $44.9 million in the prior quarter.
• Across five years, Accounts Payables topped out at $150.3 million in Q4 2025 and bottomed at $44.9 million in Q4 2024.
• Historically, Accounts Payables has averaged $82.8 million across 3 years, with a median of $53.2 million in 2023.
• Annual changes were most pronounced in 2024 — Accounts Payables dropped 15.54% — and 2025, when it jumped 234.66%.
• Telix Pharmaceuticals' Accounts Payables stood at $53.2 million in 2023, then retreated by 15.54% to $44.9 million in 2024, then surged by 234.66% to $150.3 million in 2025.
• Business Quant data shows TLX's Accounts Payables at $150.3 million in Q4 2025, $44.9 million in Q4 2024, and $53.2 million in Q4 2023.